Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a

Journal of Negative Results in BioMedicine

Volumn 3, Issue , 2004, Pages

  Lim, Ee Tuan ^a   Petzold, Axel ^a   Leary, Siobhan M ^a   Altmann, Daniel R ^b   Keir, Geoff ^a   Thompson, Ed J ^a   Miller, David H ^a   Thompson, Alan J ^a   Giovannoni, Gavin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; PROTEIN S100B;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MEASUREMENT; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NERVE GROWTH FACTORS; S100 PROTEINS;

EID: 8844275994     PISSN: 14775751     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-5751-3-4     Document Type: Article

References (18)

1. Dayal A, Jensen M, Lledo A, Arnason B: Interferon-gammasecreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 1995, 45:2173-2177.
2. Donato R: S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001, 33:637-668.
3. European Study Group on Interferon β-1b in Secondary Progressive Multiple Sclerosis: Placebo-controlled multicentre randomised trial of interferon â-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998, 352:1491-1497.
4. Gayo A, Mozo L, Suarez A, Tunon A, Lahoz C, Gutierrez C: Interferon beta-1b treatment modulates TNF alpha and IFN gamma spontaneous gene expression in MS. Neurology 1999, 52:1764-1770.
5. Green AJ, Keir G, Thomspon EJ: A specific and sensitive ELISA for measuring S-100b incerebrospinal fluid. J Immunol Methods 1997, 205:35-41.
6. The Multiple Sclerosis Collaborative Research Group (MSCRG): Intramuscular interferon-beta-1a for disease progression in relapsing-remitting multiple sclerosis. Ann Neurol 1996, 39:285-294.
7. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ: Interferon beta-1a in primary progressive multiple sclerosis: an exploratory randomised controlled trial. Neurology 2003, 60:44-51.
8. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL: Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996, 40:846-852.
9. Lou J, Gasche Y, Zheng L, Giroud C, Morel P, Clements J, Ythier A, Grau GE: Interferon-β inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab Invest 1999, 79:1015-1025.
10. Massaro AR, Michetti F, Laudisio A, Bergonzi P: Myelin basic protein and S-100 antigen in cerebrospinal fluid of patients with multiple sclerosis in the acute phase. Ital J Neurol Sci 1985, 6:53-56.
11. Michetti F, Massaro A, Russo G, Rigon G: The S-100 antigen in cerebrospinal fluid as a possible index of cell injury in the nervous system. J Neurol Sci 1980, 44:259-263.
12. Panitch H, Hirsch R, Schindler J, Johnson K: Treatment of multiple sclerosis with gamma interferon: exarcebations associated with activation of the immune system. Neurology 1987, 37:1097-1102.
13. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH, Cuzner ML, Polman CH, Uitdehaag BM, Thompson EJ, Giovannoni G: Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002, 125:1462-1473.
14. PRISMS Study Group: Randomised double-blind placebo-controlled study of interferon â-1a in relapsing-remitting multiple sclerosis. Lancet 1998, 352:1498-1504.
15. Schmidt S: S100B: pathogenetic and pathophysiologic significance in neurology. Nervenarzt 1998, 69:639-646.
16. Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, Yong VW: Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996, 40:853-863.
17. The INFB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: Clinical results of a multicenter, randomized, double blind, placebocontrolled trial. Neurology 1993, 43:655-661.
18. Uhm JH, Dooley NP, Stuve O, Francis GS, Duquette P, Antel JP, Yong VW: Migratory behaviour of lymphocytes isolated from multiple sclerosis: effects of interferon beta-1b therapy. Ann Neurol 1999, 46:319-324.